GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Orphazyme AS (CHIX:ORPHAc) » Definitions » Cash, Cash Equivalents, Marketable Securities

Orphazyme AS (CHIX:ORPHAC) Cash, Cash Equivalents, Marketable Securities : kr49.53 Mil (As of Jun. 2022)


View and export this data going back to 2021. Start your Free Trial

What is Orphazyme AS Cash, Cash Equivalents, Marketable Securities?

Orphazyme AS's quarterly cash, cash equivalents, marketable securities declined from Jun. 2021 (kr334.18 Mil) to Dec. 2021 (kr102.26 Mil) but then stayed the same from Dec. 2021 (kr102.26 Mil) to Jun. 2022 (kr49.53 Mil).

Orphazyme AS's annual cash, cash equivalents, marketable securities increased from Dec. 2019 (kr123.59 Mil) to Dec. 2020 (kr726.93 Mil) but then declined from Dec. 2020 (kr726.93 Mil) to Dec. 2021 (kr102.26 Mil).


Orphazyme AS Cash, Cash Equivalents, Marketable Securities Historical Data

The historical data trend for Orphazyme AS's Cash, Cash Equivalents, Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Orphazyme AS Cash, Cash Equivalents, Marketable Securities Chart

Orphazyme AS Annual Data
Trend Jun14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Cash, Cash Equivalents, Marketable Securities
Get a 7-Day Free Trial 631.74 394.71 123.59 726.93 102.26

Orphazyme AS Semi-Annual Data
Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22
Cash, Cash Equivalents, Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 610.45 726.93 334.18 102.26 49.53

Orphazyme AS Cash, Cash Equivalents, Marketable Securities Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.


Orphazyme AS  (CHIX:ORPHAc) Cash, Cash Equivalents, Marketable Securities Explanation

Marketable securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.


Orphazyme AS Cash, Cash Equivalents, Marketable Securities Related Terms

Thank you for viewing the detailed overview of Orphazyme AS's Cash, Cash Equivalents, Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.


Orphazyme AS Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Orphazyme AS (CHIX:ORPHAc) » Definitions » Cash, Cash Equivalents, Marketable Securities
Comparable Companies
Traded in Other Exchanges
N/A
Address
Ole Maaloes Vej 3, Copenhagen, DNK, DK-2200
Orphazyme AS is a late-stage biopharmaceutical company engaged in the development and commercialization of novel therapeutics for the treatment of neurodegenerative rare diseases. The company's lead candidate, Arimoclomol, is in development for severe orphan diseases: Niemann-Pick disease Type C (NPC), Amyotrophic Lateral Sclerosis (ALS), and Inclusion Body Myositis (IBM).

Orphazyme AS Headlines

No Headlines